GlassScriptPhysician profile
Shivani Verma
NPI 1275832677
$6,483.34
in general payments reported to CMS, 2019-2025
30 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $722 · 2021: $1,096 · 2022: $1,505 · 2023: $662 · 2024: $847 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.28 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,742.47 | 2021-2025 | Symplicity G3, Onyx Frontier, Telescope |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $979.90 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $556.47 | 2022-2025 | |
| Boston Scientific Corporation | $470.14 | 2021-2025 | Watchman Flx |
| Abiomed | $323.34 | 2022-2025 | |
| Philips North America LLC | $309.12 | 2022-2025 | Igt Devices Undivided, Coronary Other |
| Medtronic Vascular, INC. | $292.59 | 2020 | |
| Novartis Pharmaceuticals Corporation | $228.37 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $222.29 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $217.12 | 2019-2025 | Andexxa, Farxiga |
| Amgen INC. | $215.95 | 2021-2023 | Repatha |
| Penumbra, INC. | $147.06 | 2020-2023 | Indigo System |
| Jazz Pharmaceuticals INC. | $121.80 | 2019 | |
| Merck Sharp & Dohme LLC | $106.51 | 2021-2023 | Verquvo |
| Lilly USA, LLC | $57.30 | 2024 | Mounjaro, Zepbound |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spectrawave, INC | $52.46 | 2024 | Starlight Imaging Catheter, Hypervue Imaging System |
| Abbott Laboratories | $50.52 | 2021-2023 | Mitraclip |
| Heartflow, INC. | $49.82 | 2024-2025 | |
| Cook Incorporated | $47.68 | 2022 | |
| Pfizer INC. | $47.37 | 2021 | |
| Irhythm Technologies, INC. | $37.32 | 2021-2022 | |
| Terumo Medical Corporation | $32.25 | 2025 | Angio-Seal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.34 | 2022 | |
| Atricure, INC. | $25.97 | 2023 | |
| Sanofi-Aventis U.S. LLC | $25.00 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $24.67 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $21.72 | 2024 | Arcalyst |
| Xeris Pharmaceuticals, INC. | $21.30 | 2025 | Gvoke Hypopen |
| W. L. Gore & Associates, INC. | $15.63 | 2024 | Gore Cardioform Septal Occluder |
| E.R. Squibb & Sons, L.L.C. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.